These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17269928)

  • 1. Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency.
    Zhang MY; Dimitrov DS
    Curr Pharm Des; 2007; 13(2):203-12. PubMed ID: 17269928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
    Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
    Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody.
    Zhang MY; Xiao X; Sidorov IA; Choudhry V; Cham F; Zhang PF; Bouma P; Zwick M; Choudhary A; Montefiori DC; Broder CC; Burton DR; Quinnan GV; Dimitrov DS
    J Virol; 2004 Sep; 78(17):9233-42. PubMed ID: 15308718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.
    Zhang MY; Yuan T; Li J; Rosa Borges A; Watkins JD; Guenaga J; Yang Z; Wang Y; Wilson R; Li Y; Polonis VR; Pincus SH; Ruprecht RM; Dimitrov DS
    PLoS One; 2012; 7(9):e44241. PubMed ID: 22970187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.
    Zhang MY; Choudhry V; Sidorov IA; Tenev V; Vu BK; Choudhary A; Lu H; Stiegler GM; Katinger HW; Jiang S; Broder CC; Dimitrov DS
    J Immunol Methods; 2006 Dec; 317(1-2):21-30. PubMed ID: 17078964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning.
    Zhang MY; Shu Y; Rudolph D; Prabakaran P; Labrijn AF; Zwick MB; Lal RB; Dimitrov DS
    J Mol Biol; 2004 Jan; 335(1):209-19. PubMed ID: 14659751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.
    Zhang MY; Vu BK; Choudhary A; Lu H; Humbert M; Ong H; Alam M; Ruprecht RM; Quinnan G; Jiang S; Montefiori DC; Mascola JR; Broder CC; Haynes BF; Dimitrov DS
    J Virol; 2008 Jul; 82(14):6869-79. PubMed ID: 18480433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
    Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
    J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and phenotypic characterization of HIV type 1 functional envelope clones of subtypes G and F.
    Revilla A; Delgado E; Christian EC; Dalrymple J; Vega Y; Carrera C; González-Galeano M; Ocampo A; de Castro RO; Lezaún MJ; Rodríguez R; Mariño A; Ordóñez P; Cilla G; Cisterna R; Santamaría JM; Prieto S; Rakhmanova A; Vinogradova A; Ríos M; Pérez-Álvarez L; Nájera R; Montefiori DC; Seaman MS; Thomson MM
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):889-901. PubMed ID: 21226626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.
    Binley JM; Wrin T; Korber B; Zwick MB; Wang M; Chappey C; Stiegler G; Kunert R; Zolla-Pazner S; Katinger H; Petropoulos CJ; Burton DR
    J Virol; 2004 Dec; 78(23):13232-52. PubMed ID: 15542675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
    Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.
    Klein JS; Gnanapragasam PN; Galimidi RP; Foglesong CP; West AP; Bjorkman PJ
    Proc Natl Acad Sci U S A; 2009 May; 106(18):7385-90. PubMed ID: 19372381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.
    Chen Y; Zhang J; Hwang KK; Bouton-Verville H; Xia SM; Newman A; Ouyang YB; Haynes BF; Verkoczy L
    J Immunol; 2013 Aug; 191(3):1260-75. PubMed ID: 23825311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18.
    Gift SK; Zentner IJ; Schön A; McFadden K; Umashankara M; Rajagopal S; Contarino M; Duffy C; Courter JR; Zhang MY; Gershoni JM; Cocklin S; Dimitrov DS; Smith AB; Freire E; Chaiken IM
    Biochemistry; 2011 Apr; 50(14):2756-68. PubMed ID: 21351734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
    Nyambi PN; Mbah HA; Burda S; Williams C; Gorny MK; Nádas A; Zolla-Pazner S
    J Virol; 2000 Aug; 74(15):7096-107. PubMed ID: 10888650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity.
    Xiao X; Phogat S; Shu Y; Phogat A; Chow YH; Wei OL; Goldstein H; Broder CC; Dimitrov DS
    Vaccine; 2003 Oct; 21(27-30):4275-84. PubMed ID: 14505910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.
    Varadarajan R; Sharma D; Chakraborty K; Patel M; Citron M; Sinha P; Yadav R; Rashid U; Kennedy S; Eckert D; Geleziunas R; Bramhill D; Schleif W; Liang X; Shiver J
    J Virol; 2005 Feb; 79(3):1713-23. PubMed ID: 15650196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.